US OptionsDetailed Quotes
ARQT250117C10000
- 3.80
- -0.05-1.30%
15min DelayClose Jan 17 16:00 ET
3.80High3.80Low
3.80Open3.85Pre Close40 Volume546 Open Interest10.00Strike Price15.20KTurnover0.00%IV8.83%PremiumJan 17, 2025Expiry Date2.68Intrinsic Value100Multiplier-1DDays to Expiry1.12Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.06Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Arcutis Biotherapeutics Stock Discussion
Sign in to post a comment
$Quoin Pharmaceuticals (QNRX.US)$ $Bridger Aerospace (BAER.US)$ $Mill City Ventures III (MCVT.US)$ $Elevation Oncology (ELEV.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $QMMM Holdings (QMMM.US)$ $Heramba Electric (PITA.US)$ $Black Diamond Therapeutics (BDTX.US)$ $Intra-Cellular Therapies (ITCI.US)$ $Traws Pharma (TRAW.US)$ $Sage Therapeutics (SAGE.US)$ $Glucotrack (GCTK.US)$ $Algorhythm (RIME.US)$ $Agape ATP (ATPC.US)$
📊⚡️📊
📊⚡️📊
4
1
$Arcutis Biotherapeutics (ARQT.US)$
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Positive
▪️Q4 2024 revenue grew 366% YoY to $63 million
▪️Full-year 2024 revenue increased 449% YoY to $160 million
▪️Strong quarter-over-quarter growth of 41% in Q4 2024
▪️Robust liquidity position of $329 million including available debt
▪️Option to re-draw $100 million deb...
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Positive
▪️Q4 2024 revenue grew 366% YoY to $63 million
▪️Full-year 2024 revenue increased 449% YoY to $160 million
▪️Strong quarter-over-quarter growth of 41% in Q4 2024
▪️Robust liquidity position of $329 million including available debt
▪️Option to re-draw $100 million deb...
3
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
73
30
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Arcutis Biotherapeutics (ARQT.US)$
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
$Arcutis Biotherapeutics (ARQT.US)$ Blackrock bought over 9mil shares today.
$Arcutis Biotherapeutics (ARQT.US)$ Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
2
2
$Arcutis Biotherapeutics (ARQT.US)$ Shorts will suffer
2
$Arcutis Biotherapeutics (ARQT.US)$
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
1
No comment yet
MommaCrazy : give it time... they may short it down to steal a ton of shares. They do this on ARQT and my dumb butt averaged up.